Lonodelestat Safely Blocks Inflammatory Marker in CF Patients in Early Trial
Lonodelestat (also known as POL6014), Santhera Pharmaceuticals’ investigational therapy to treat chronic lung inflammation, was safe and...
Girls With CF Need Reproductive Counseling, Study Asserts
Female adolescents with cystic fibrosis (CF) should be offered contraceptive counseling and informed about pregnancy risks, a long-term...
ELX-02 Restores CFTR Activity in Organoids With G542X Mutations, Study Finds
ELX-02 restored the levels and function of CFTR — the defective protein in CF — in “mini-organs,” or organoids, derived from patients...
The Middle East CF Association
The Middle East CF Association (MECFA) is working to make lives better for people with cystic fibrosis. Christine Noke is the co-founder...
Protalix, SarcoMed Partner to Advance PRX-110 for Pulmonary Sarcoidosis
Protalix Biotherapeutics and SarcoMed USA have entered into an exclusive worldwide license agreement to advance PRX-110 (alidornase alfa)...
Electromed Resumes Study of SmartVest
Electromed has resumed a study seeking to assess the effects of SmartVest, an inflatable vest that can be used to deliver high-frequency...
Tobramycin, Inhaled Antibiotic, Eases Symptoms, Study in Off-label Use Finds
Off-label use of the inhaled antibiotic tobramycin lowered sputum production, and eased shortness of breath, and cough in people with...
UK Trial to Investigate Safety of Lowering CF Treatment Burden via Kaftrio
The National Institute for Health Research (NIHR) awarded a grant worth more than £1.5 million (about $2.1 million) to support a U.K....
Safety, tolerability of combination therapy sustained in children with cystic fibrosis
Combination therapy with lumacaftor/ivacaftor was safe and well tolerated for up to 120 weeks in children aged 6 to 11 years with the...
CF Foundation Has Awarded Up to $3M to Kinnear Pharmaceuticals for Anti-Infective
The Cystic Fibrosis Foundation has awarded up to $3 million to Kinnear Pharmaceuticals to conduct preclinical testing of a broad-spectrum...
